Faculty Opinions recommendation of Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.

2012 ◽  
Author(s):  
David Goldsmith
Keyword(s):  
Systematic Review ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Meta Analysis ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy

LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy

2012 ◽  
Vol 47 (1) ◽  
pp. 117-123 ◽  
Author(s):  
Angelo Zinellu ◽  
Salvatore Sotgia ◽  
Elisabetta Pisanu ◽  
Giacomina Loriga ◽  
Luca Deiana ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy

Lipid disorders of patients with chronic kidney disease

2015 ◽  
Author(s):  
Alan G. Jardine ◽  
Rajan K. Patel
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
Coronary Disease ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Strong Argument ◽  
Lowering Therapy ◽  
Coronary Events ◽  
Cv Disease

The risk of developing cardiovascular (CV) disease is increased in patients with chronic kidney disease (CKD) and although dyslipidaemia is a major contributory factor to the development of premature CV disease, the relationship is complex. Changes in lipid fractions are related to glomerular filtration rate and the presence and severity of proteinuria, diabetes, and other confounding factors. The spectrum of CV disease changes from lipid-dependent, atheromatous coronary disease in early CKD to lipid-independent, non-coronary disease, manifesting as heart failure, and sudden cardiac death in advanced and end-stage renal disease. Statin-based lipid-lowering therapy is proven to reduce coronary events across the spectrum of CKD. The relative reduction in overall CV events, however, diminishes as CKD progresses and the proportion of lipid-dependent coronary events declines. There is nevertheless a strong argument for the use of statin-based therapy across the spectrum of CKD. The argument is particularly strong for those patients with progressive renal disease who will eventually require transplantation, in whom preventive therapy should start as early as possible. The SHARP study established the benefits and endorses the use of lipid-lowering therapy in CKD 3-4 but uncertainty about the value of initiation of statin therapy in CKD 5 remains. There is, however, no rationale for stopping agents started earlier in the course of the illness for compelling indications, particularly in those who will ultimately be transplanted. The place of high-density lipoprotein-cholesterol raising and triglyceride lowering therapy needs to be assessed in trials. Modifying dyslipidaemia in CKD has demonstrated that lipid-dependent atheromatous cardiovascular disease is only one component of the burden of CV disease in CKD patients, that this is proportionately less in advanced CKD, and that modification of lipid profiles is only one part of CV risk management.

Lipid-Lowering Therapy in Persons With Chronic Kidney Disease

2012 ◽  
Vol 157 (4) ◽  
pp. 251 ◽  
Author(s):  
Ashish Upadhyay ◽  
Amy Earley ◽  
Jenny L. Lamont ◽  
Shana Haynes ◽  
Christoph Wanner ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy

scholarly journals Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis

Renal Failure ◽  
2018 ◽  
Vol 40 (1) ◽  
pp. 289-297 ◽  
Author(s):  
Xuemei Liu ◽  
Tingting Zhai ◽  
Ruixia Ma ◽  
Congjuan Luo ◽  
Huifang Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Kidney Disease ◽  
Meta Analysis ◽  
Lowering Therapy

scholarly journals EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

2013 ◽  
Vol 12 (4) ◽  
pp. 75-78
Author(s):  
A. Catapano ◽  
E. V. Shlyakhto ◽  
A. I. Martynov ◽  
R. G. Oganov ◽  
V. V. Kukharchuk ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Lipid Metabolism ◽  
Kidney Disease ◽  
Expert Consensus ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy

Expert Consensus. Role of combination lipid-lowering therapy (simvastatin/ezetimibe 20/10 mg) in the correction of lipid metabolism disturbances in patients with chronic kidney disease.

scholarly journals Is Non Dipping Hypertension Associated with Dyslipidemia, Type 2 Diabetes or Chronic Kidney Disease?

2013 ◽  
Vol 20 (3) ◽  
pp. 331-337
Author(s):  
Mirela – Nicoleta Tudor ◽  
Maria Francisca Navajas Martinez ◽  
Adina Mitrea ◽  
Eugen Moţa
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Lipid Lowering ◽  
Study Group ◽  
Lipid Lowering Therapy ◽  
University Campus ◽  
Lowering Therapy ◽  
The University

Abstract Background and aims. Hypertension and dyslipidemia (DLP) increase the risk of cardiovascular diseases (CVD), especially in patients with chronic kidney disease (CKD). A non dipping pattern is very common in CKD. The aim of the study was to determine whether there is a difference between dipping/non dipping hypertension in subjects with CKD and DLP with or without lipid-lowering therapy (LLT). Material and methods. We performed a retrospective study that included 129 subjects from the Nephrology- Hypertension Out-patient Department of the University Campus Bio-Medico, Rome from January 2011 to April 2013. Results. From a total of 129 CKD subjects, 73 (56.59%) subjects had a non dipping pattern and 56 (43.41%) had a dipper pattern. We found statistically significant differences between the dipping and non-dipping pattern in subjects with CKD stages 1-2 versus stages 3-4 (p=0.018). When we analyzed the association between non-dipping status with DLP and type 2 diabetes (T2D), we did not find a statistically significant result. Conclusions. Only CKD significantly influenced the dipping/non dipping pattern in the study group

LIPID-LOWERING THERAPY IN CHRONIC KIDNEY DISEASE: IS THERE A ROLE FOR EZETIMIBE?

2012 ◽  
Vol 38 (3) ◽  
pp. 138-146 ◽  
Author(s):  
Darren Green ◽  
Rosica Panayotova ◽  
James P. Ritchie ◽  
Edmond O’Riordan ◽  
John McDonald
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy
Sign in / Sign up

Export Citation Format

Share Document